EDITORIAL

EYE ON CHINA

• Living on a Gradient: A Glimpse on How Genetic Evolution shapes High-Altitude Tibetans' Survival
• Ascletis as the First Chinese Company to File Clinical Applications for Interferon-Free HCV Treatment
• Anti-Cancer formulation derived from Traditional Chinese Medicine receives FDA's approval for Phase III Clinical Trial
• Kunming Institute of Zoology unveils the most diverse form of HIV-1 viral strain transmission at Burma Border
• Chinese Biologists Find Duckweed to Tackle Water Pollution
• A new publication in Science on the parvalbumin-positive excitatory visual pathway

• An interview with Professor Jiang Shi-Bo on Anti-MERS-CoV
• An interview with Dr. Michael Whitt on MERS, Disease Management & Prevention.
• A conversation with: Dr. Junhui Bian Dean of Shantou University Medical College

• Some Parents don't vaccinate their Children, and why they should stop behaving like a Clown.
• "To edit or not?" - the dilemma around CRISPR

• When a Phone is more than a SmartPhone
• ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries
• New Implant Device for the Heart: World's First ProMRI Quadripolar CRT-D Now Available in Japan

AUSTRALASIA

• Mighty River Honey: Saving the Bee Through Social Enterprise

• A*STAR'S IME AND INEX Innovations Exchange to Develop Non-invasive Prenatal Diagnostic Technology
• CellResearch Corporation receives new US patent approval for exclusive stem cell technology amidst new partnerships
• A Gel That Can Make Drugs Last Longer

• Japanese Biotech JCR Pharmaceuticals Selects Medidata's Cloud-Based Platform to Power Rare Disease Clinical Research in Japan

• MedDay Reports Additional Positive Data of its Pivotal Phase III Study With MD1003 in Patients with Progressive Multiple Sclerosis

• Merck Serono Introduces New Eeva Test Version Aiming for Optimized Assisted Reproductive Outcomes

• Ebola Genome Insights Indicate that Containment Worked

• TissueGene, Inc. Announces FDA Acceptance Of Invossa. As Proprietary Name For TissueGene-C
• FDA Approves Technology Upgrade for Recipients of First Commercially Available Cochlear Implant

CONFERENCE CALENDAR